SCHEDULE: 1Globe Group Boosts Sinovac Stake Amid Legal Battles

1Globe Capital LLC, 1Globe Biomedical (Hong Kong) Company Limited, and Dr. Jiaqiang Li have increased their beneficial ownership in Sinovac Biotech Ltd. to 32.3% while actively engaged in multiple ongoing legal disputes concerning corporate control and share validity.

Summary

• 1Globe Capital LLC, 1Globe Biomedical (Hong Kong) Company Limited, and Dr. Jiaqiang Li (the "reporting persons") have filed Amendment No. 7 to their Schedule 13D regarding Sinovac Biotech Ltd.
• The reporting persons collectively beneficially own 18,515,315 common shares, representing approximately 32.3% of Sinovac's outstanding common shares.
• This percentage is calculated based on 57,281,861 common shares outstanding as of December 31, 2017, explicitly excluding shares purportedly issued after May 2018 due to ongoing litigation.
• Dr. Jiaqiang Li serves as Chairman of both 1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited, and also as Chairman of Sinovac's board of directors.
• The filing details several ongoing legal proceedings, including a civil action initiated by Vivo Capital Surplus Fund VIII, L.P. alleging disclosure violations against Dr. Li and 1Globe Capital LLC.
• The reporting persons are vigorously defending against the Vivo action, having filed a motion to dismiss and dissolve a preliminary injunction.
• There is an ongoing dispute regarding a purported "New Imposter Board" elected by a Dissenting Investor Group following an adjourned Special Meeting of Shareholders on July 8, 2025.
• The Issuer, 1Globe Capital LLC, and OrbiMed Partners Master Fund Limited have filed the "Antigua SSM Action" to challenge the validity of the "New Imposter Board" and the purported continuation of the Special Meeting.
• Additionally, the "Disputed PIPE Action" was filed on May 6, 2025, challenging the validity of certain common shares issued under a "Disputed PIPE" and seeking rectification of the shareholder register.
• The reporting persons entered into a Joint Filing Agreement on September 12, 2025, for joint Schedule 13D filings.
• No transactions in Sinovac securities were engaged in by the reporting persons during the past 60 days.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to the extensive and ongoing legal disputes, which signal significant corporate governance issues and create substantial uncertainty for Sinovac Biotech Ltd. and its shareholders.

Positives

• The reporting persons maintain a significant beneficial ownership stake of 32.3% in Sinovac Biotech Ltd., indicating strong conviction in the company's long-term value.
• Dr. Jiaqiang Li, as Chairman of the reporting entities and the Issuer's board, provides consistent leadership and alignment of interests.
• The reporting persons are actively defending against legal challenges, demonstrating their commitment to protecting their investment and corporate governance.

Negatives

• Multiple ongoing and complex legal disputes create significant uncertainty and potential for prolonged litigation costs for Sinovac Biotech Ltd.
• Allegations of disclosure violations against Dr. Li and 1Globe Capital LLC by Vivo Capital Surplus Fund VIII, L.P. could impact investor confidence.
• The dispute over the validity of the "New Imposter Board" and the Special Meeting highlights severe corporate governance issues and internal conflict within the company.
• The challenge to the "Disputed PIPE" raises questions about the validity of previously issued shares and the accuracy of the shareholder register, potentially affecting share dilution and ownership percentages.
• The calculation of beneficial ownership excludes shares purportedly issued after May 2018 due to litigation, indicating a lack of clarity on the true total outstanding shares.

Risks

• Litigation Risk: Ongoing civil actions (Vivo Action, Antigua SSM Action, Disputed PIPE Action) could result in adverse judgments, significant legal expenses, and diversion of management attention.
• Corporate Governance Instability: The dispute over the "New Imposter Board" and the validity of shareholder meetings creates uncertainty regarding company leadership and decision-making.
• Share Dilution/Ownership Uncertainty: The "Disputed PIPE Action" challenges the validity of certain share issuances, which could lead to changes in the total outstanding shares and impact existing shareholders' proportional ownership.
• Regulatory Scrutiny: Allegations of Section 13(d) disclosure violations could attract further regulatory attention from the SEC.
• Reputational Damage: The public nature of these disputes and allegations could harm Sinovac's reputation and investor confidence.

Future Outlook

The reporting persons state they purchased securities believing they were undervalued and represented an attractive investment opportunity. They may endeavor to increase or decrease their position based on market conditions and other investment opportunities. Beyond this, no specific future plans or proposals are outlined, other than those related to the ongoing legal actions and defending their position.

Management Comments

• "1Globe Capital LLC and Dr. Li dispute Vivo Fund VIII's claim and intend to vigorously defend against it."
• "The reporting persons do not believe the New Imposter Board has been validly elected and support the current Board installed by the Privy Council's Order and per Antiguan law."
• "The reporting persons purchased the securities of the Issuer reported herein based on the reporting persons' belief that the securities, when purchased, were undervalued and represented an attractive investment opportunity."
• "The reporting persons, at any time and from time to time, may review, reconsider and change their intention with respect to any and all matters referred to in Item 4."

Industry Context

StockSavvy.ai notes that the biotech industry, particularly companies involved in vaccine development like Sinovac, often face intense competition and regulatory scrutiny. Shareholder activism and corporate control battles, as seen in this filing, can significantly distract management and impact operational focus, potentially hindering a company's ability to capitalize on market opportunities or respond to industry-specific challenges. The ongoing disputes highlight the complexities of corporate governance in international companies with diverse investor bases.

Comparison to Industry Standards

• The level of beneficial ownership (32.3%) by an activist group like 1Globe Capital LLC is substantial and typically indicates a strong intent to influence corporate strategy, which is common in situations where investors perceive undervaluation or mismanagement. For example, Carl Icahn's significant stakes in companies like Xerox or Herbalife often lead to similar governance battles.
• The multiple layers of litigation, including challenges to board elections and share issuances (Disputed PIPE), are indicative of a highly contentious corporate control struggle, reminiscent of historical proxy fights seen in companies like Yahoo! or DuPont, where significant shareholder value can be eroded by legal costs and management distraction.
• The reliance on a 2017 share count for beneficial ownership calculation, while acknowledging ongoing litigation over subsequent share issuances, is an unusual practice that underscores the deep-seated governance issues and lack of consensus on fundamental company metrics, diverging from standard transparent reporting practices in mature markets.

Management Changes

Corporate Governance

Legal Proceedings

• Vivo Action: A civil action initiated by Vivo Capital Surplus Fund VIII, L.P. on April 14, 2025, with an amended complaint filed on July 25, 2025, alleging disclosure violations under Section 13(d) against Dr. Li and 1Globe Capital LLC. 1Globe Capital LLC and Dr. Li dispute the claim and filed a motion to dismiss and dissolve a preliminary injunction on August 15, 2025. Vivo filed opposition on August 29, 2025, and a reply was filed on September 10, 2025.
• Antigua SSM Action: Filed on August 11, 2025, by the Issuer, 1Globe Capital LLC, and OrbiMed Partners Master Fund Limited against SAIF and members of the "New Imposter Board." This action challenges the purported continuation of the Special Meeting of Shareholders on July 8, 2025, and the alleged election of the "New Imposter Board," seeking declarations of invalidity. The action is currently pending.
• Disputed PIPE Action: Filed on May 6, 2025, by the Issuer, 1Globe Capital LLC, and OrbiMed Partners Master Fund Limited against Vivo Capital LLC and related entities. This action challenges the validity of the "Disputed PIPE" (Private Investment in Public Equity) and seeks to set aside the common shares issued under it and rectify the Issuer's register of shareholders. The action is currently pending.

Related Party Transactions

• The filing mentions "Relative Shares" (5,702,460 Common Shares) held by relatives of Dr. Li, which are included in his beneficial ownership calculation due to an SEC order.
• "Subject Shares" held by CDH Utopia Limited, where 1Globe Biomedical (Hong Kong) Company Limited possesses voting rights in 70% of these shares and certain financial upside for the total 6,000,000 Common Shares. Dr. Li may be deemed to beneficially own these shares.

Stakeholder Impact

• Shareholders: Face significant uncertainty due to ongoing legal disputes over corporate control, board legitimacy, and the validity of share issuances, potentially impacting share value and voting rights.
• Management/Employees: May experience distraction and instability due to the intense corporate governance battles and legal proceedings, potentially affecting operational focus and morale.
• Creditors/Investors: May view the company with increased caution due to the high level of internal conflict and legal risks, potentially impacting access to capital or credit terms.
• Regulatory Authorities: The ongoing allegations of disclosure violations and corporate governance issues could lead to continued scrutiny from the SEC and other regulatory bodies.

Next Steps

• 1Globe Capital LLC and Dr. Li intend to vigorously defend against the Vivo Action.
• The Antigua SSM Action, challenging the "New Imposter Board," is currently pending.
• The Disputed PIPE Action, challenging the validity of certain share issuances, is currently pending.
• Reporting persons may endeavor to increase or decrease their position in Sinovac through open market or private transactions.

Key Dates

Recommendation

The filing highlights a deeply entrenched corporate control battle with multiple ongoing legal proceedings challenging board legitimacy, share issuances, and disclosure compliance. While the reporting persons maintain a significant stake and express belief in undervaluation, the pervasive uncertainty and potential for prolonged litigation create substantial risk. An investor should hold their position to monitor the outcomes of these critical legal disputes, as their resolution will significantly impact the company's governance, capital structure, and future strategic direction. Until there is greater clarity on these fundamental issues, a more definitive recommendation is premature.

Keywords

Sinovac Biotech Ltd., SVA, Schedule 13D/A, Beneficial Ownership, 1Globe Capital LLC, Jiaqiang Li, Corporate Governance, Shareholder Dispute, Litigation, SEC Filing, Biotech, Vaccines, China, Antigua and Barbuda